Gilead Sciences (France)
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Gilead Sciences (France), France, covering academic research published from 2000 to 2024. Read More.
Open Access Percentage
56%
Total
Publications
235
Total Open
Publications
131
Total
Citations
7K
Open Access
Percentage
56%
Total
Publications
235
Total Open
Publications
131
Total
Citations
7K
Breakdown
Publisher Open
35%
Both
16%
Other Platform Open
5%
Closed
44%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 24%
29
Hybrid 25%
30
No Guarantees 51%
61
Other Platform Open
Domain 84%
41
Institution 22%
11
Other Internet 16%
8
Preprint 4%
2
Public 4%
2
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 41 |
Europe PMC | Domain | 20 |
University of California - eScholarship University of California | Institution | 4 |
DOI | Other Internet | 3 |
University of Zurich - Zurich Open Repository and Archive | Institution | 2 |
University of Toronto - TSpace | Institution | 2 |
University of Michigan - Deep Blue | Institution | 2 |
University of Bristol - Bristol Research | Institution | 2 |
Semantic Scholar | Public | 2 |
Le Centre pour la Communication Scientifique Directe - HAL - TYPE ART | Other Internet | 2 |